Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumours: Standardized and Randomized, or Personalized?

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2013 Nov 14

PMID 24221244

Citations 13

Authors

Michael S Hofman

Rodney J Hicks

Affiliations

Soon will be listed here.

Citing Articles

Tumor Sink Effect with Prostate-Specific Membrane Antigen-Targeted Theranostics in Patients with Metastatic Castration-Resistant Prostate Cancer: Intra-Individual Evaluations.

Burgard C, Rosar F, Marlowe R, Bartholoma M, Dewes S, Schaefer-Schuler A Cancers (Basel). 2023; 15(9).

PMID: 37174058 PMC: 10177482. DOI: 10.3390/cancers15092592.

Practical kidney dosimetry in peptide receptor radionuclide therapy using [Lu]Lu-DOTATOC and [Lu]Lu-DOTATATE with focus on uncertainty estimates.

Staanum P, Frellsen A, Olesen M, Iversen P, Arveschoug A EJNMMI Phys. 2021; 8(1):78.

PMID: 34773508 PMC: 8590641. DOI: 10.1186/s40658-021-00422-2.

Tumor Sink Effect in Ga-PSMA-11 PET: Myth or Reality?.

Gafita A, Wang H, Robertson A, Armstrong W, Zaum R, Weber M J Nucl Med. 2021; 63(2):226-232.

PMID: 34049987 PMC: 8805781. DOI: 10.2967/jnumed.121.261906.

Enhancing the anti-tumour activity of Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP.

Cullinane C, Waldeck K, Kirby L, Rogers B, Eu P, Tothill R Sci Rep. 2020; 10(1):10196.

PMID: 32576907 PMC: 7311440. DOI: 10.1038/s41598-020-67199-9.

Theranostic implications of molecular imaging phenotype of well-differentiated pulmonary carcinoid based on Ga-DOTATATE PET/CT and F-FDG PET/CT.

Zidan L, Iravani A, Kong G, Akhurst T, Michael M, Hicks R Eur J Nucl Med Mol Imaging. 2020; 48(1):204-216.

PMID: 32572559 DOI: 10.1007/s00259-020-04915-7.

References

Smith G, Pell J . Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. BMJ. 2003; 327(7429):1459-61. PMC: 300808. DOI: 10.1136/bmj.327.7429.1459. View

Brizzi M, Berruti A, Ferrero A, Milanesi E, Volante M, Castiglione F . Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network. BMC Cancer. 2009; 9:388. PMC: 2776604. DOI: 10.1186/1471-2407-9-388. View

Hicks R . Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy. Cancer Imaging. 2010; 10 Spec no A:S83-91. PMC: 2967140. DOI: 10.1102/1470-7330.2010.9007. View

Delpassand E, Samarghandi A, Mourtada J, Zamanian S, Espenan G, Sharif R . Long-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 Pentetreotide. Theranostics. 2012; 2(5):472-80. PMC: 3364554. DOI: 10.7150/thno.3739. View

Hubble D, Kong G, Michael M, Johnson V, Ramdave S, Hicks R . 177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide. Eur J Nucl Med Mol Imaging. 2010; 37(10):1869-75. DOI: 10.1007/s00259-010-1483-4. View

Krenning E, Kwekkeboom D, Bakker W, Breeman W, Kooij P, Oei H . Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993; 20(8):716-31. DOI: 10.1007/BF00181765. View

Romer A, Seiler D, Marincek N, Brunner P, Koller M, Ng Q . Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013; 41(2):214-22. DOI: 10.1007/s00259-013-2559-8. View

Cwikla J, Sankowski A, Seklecka N, Buscombe J, Nasierowska-Guttmejer A, Jeziorski K . Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. Ann Oncol. 2009; 21(4):787-794. DOI: 10.1093/annonc/mdp372. View

Rinke A, Muller H, Schade-Brittinger C, Klose K, Barth P, Wied M . Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009; 27(28):4656-63. DOI: 10.1200/JCO.2009.22.8510. View

10.

Raymond E, Dahan L, Raoul J, Bang Y, Borbath I, Lombard-Bohas C . Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364(6):501-13. DOI: 10.1056/NEJMoa1003825. View

11.

Strosberg J, Fine R, Choi J, Nasir A, Coppola D, Chen D . First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2010; 117(2):268-75. PMC: 4665634. DOI: 10.1002/cncr.25425. View

12.

Kwekkeboom D, Teunissen J, Bakker W, Kooij P, de Herder W, Feelders R . Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005; 23(12):2754-62. DOI: 10.1200/JCO.2005.08.066. View

13.

Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H . Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011; 29(17):2416-23. DOI: 10.1200/JCO.2010.33.7873. View

14.

Horsch D, Ezziddin S, Haug A, Gratz K, Dunkelmann S, Krause B . Peptide receptor radionuclide therapy for neuroendocrine tumors in Germany: first results of a multi-institutional cancer registry. Recent Results Cancer Res. 2012; 194:457-65. DOI: 10.1007/978-3-642-27994-2_25. View

15.

Claringbold P, Brayshaw P, Price R, Turner J . Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2010; 38(2):302-11. DOI: 10.1007/s00259-010-1631-x. View

16.

Beauregard J, Hofman M, Kong G, Hicks R . The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2011; 39(1):50-6. DOI: 10.1007/s00259-011-1937-3. View

17.

Seregni E, Maccauro M, Coliva A, Castellani M, Bajetta E, Aliberti G . Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results. Q J Nucl Med Mol Imaging. 2010; 54(1):84-91. View

18.

Hofman M, Hicks R . Changing paradigms with molecular imaging of neuroendocrine tumors. Discov Med. 2012; 14(74):71-81. View

19.

Yao J, Shah M, Ito T, Bohas C, Wolin E, Van Cutsem E . Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364(6):514-23. PMC: 4208619. DOI: 10.1056/NEJMoa1009290. View